<DOC>
	<DOCNO>NCT00651482</DOCNO>
	<brief_summary>To determine safety efficacy combination bevacizumab everolimus ( RAD001 ) treatment metastatic renal cell cancer</brief_summary>
	<brief_title>Treatment Refractory Metastatic Renal Cell Carcinoma With Bevacizumab RAD001 ( Everolimus )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Signed Informed Consent Form Histologically confirm metastatic RCC predominantly clear cell Measurable disease , define RECIST Age ≥ 18 year ECOG performance status 0 1 No 1 prior target therapy ( eg , sorafenib , sunitinib ) ( prior cytokine therapy allow ) No 2 prior systemic therapy Ability capacity comply study followup procedures General Exclusion Criteria Inability comply study and/or followup procedure Life expectancy &lt; 12 week Inadequate organ function , evidence follow screening : Absolute neutrophil count ( ANC ) &lt; 1500/uL Platelet count ≤ 100 x 10^9/L Total bilirubin ≥ 1.5 x upper limit normal ( ULN ) AST and/or ALT &gt; 2.5 x ULN patient without evidence liver metastasis , 5 x ULN patient document liver metastasis Serum creatinine &gt; 2.0 mg/dL Hemoglobin &lt; 9 g/dL ( may transfuse receive epoetin alfa maintain exceed level ) Active infection fever &gt; 38.5°C within 3 day start treatment Women pregnant breast feeding , Able conceive unwilling practice effective method birth control . History malignancy within 5 year prior Day 1 except tumor negligible risk metastasis death , adequately control basal cell carcinoma , squamouscell carcinoma skin , carcinoma situ cervix , earlystage bladder cancer , lowgrade endometrial cancer Malignancies undergone putative surgical cure ( i.e. , localized prostate cancer postprostatectomy ) within 5 year prior Day 1 may discuss Principal Investigator . Any medical condition ( include mental illness substance abuse ) deem clinician likely interfere patient 's ability provide inform consent , cooperate , participate study , interfere interpretation result . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study DiseaseSpecific Exclusion Criteria RCC predominantly sarcomatoid feature Radiotherapy RCC within 28 day prior Day 1 , exception singlefraction radiotherapy give indication pain control Prior treatment bevacizumab mTOR inhibitor ( eg , temsirolimus , sirolimus , everolimus ) Current need dialysis BevacizumabSpecific Exclusions Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) Any prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment Known CNS disease , except treat brain metastasis . Treated brain metastasis define evidence progression hemorrhage treatment ongoing requirement dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period . Anticonvulsants ( stable dose ) allow . Treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS ; Gamma Knife , LINAC , equivalent ) combination deem appropriate treating physician . Patients CNS metastasis treat neurosurgical resection brain biopsy perform within 3 month prior Day 1 exclude . Significant vascular disease ( eg , aortic aneurysm , aortic dissection ) Symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy intentionally pharmacologicallyinduced Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment Serious , nonhealing wound , ulcer , bone fracture Proteinuria screening demonstrate urine protein : Creatinine ( UPC ) ratio ≥ 1.0 . If UPC ratio ≥ 1.0 , patient must undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible . Known hypersensitivity component bevacizumab RAD001Specific Exclusion Criteria Known hypersensitivity component RAD001 Chronic treatment systemic steroid another immunosuppressive agent Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 ( eg , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) Severely impaired lung function ( spirometry DLCO &lt; 50 % normal O2 saturation 88 % less rest room air ) If O2 saturation ≤ 88 % rest screening , pulmonary function test ( PFTs ) order confirm normal pulmonary function eligibility . Fasting total cholesterol &gt; 350 mg/dL Fasting triglyceride level &gt; 400 mg/dL &gt; 2.5 x ULN Fasting serum glucose &gt; 250 mg/dL Serum phosphorus &lt; 2.0 mg/dL Serum correct calcium &lt; 8.0 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>